Sani H. Kizilbash

Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

Shiv K. Gupta, Sani H. Kizilbash, Brett L. Carlson et al. · JNCI Journal of the National Cancer Institute · 2015 · 120 citations · Full text

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Karen E. Parrish, Ling Cen, J. C. Murray et al. · Molecular Cancer Therapeutics · 2015 · 86 citations · Full text

Pharmacotherapy, High-grade Gliomas, Glioma +18

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity

Shiv K. Gupta, Emily J. Smith, Ann C. Mladek et al. · Frontiers in Oncology · 2019 · 79 citations · Full text

Discordant <i>In Vitro</i> and <i>In Vivo</i> Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson et al. · Clinical Cancer Research · 2014 · 76 citations

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study

Andres Ramos‐Fresnedo, Michael W. Pullen, Carlos Perez‐Vega et al. · Journal of Neuro-Oncology · 2022 · 72 citations

Neuro-oncology, Glioma, Tumor Heterogeneity +10